McKesson Corporation (MCK): Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
McKesson Corporation (MCK), headquartered in Irving, Texas, is a leading healthcare services provider with a legacy dating back to 1833. Specializing in the medical distribution industry, McKesson offers a range of vital services, including the distribution of pharmaceutical products and healthcare-related consulting. The U.S. Pharmaceutical segment focuses on an extensive array of drugs and technology solutions, while the Prescription Technology Solutions segment enhances connectivity between patients, pharmacies, and biopharma companies to improve medication access. McKesson’s dedication to innovation positions it strategically within the healthcare sector, contributing significantly to improved patient health outcomes.
Financial Performance & Market Outlook
As of now, McKesson reports a total revenue of approximately $313.75 billion, underscoring robust financial health and market activity. Analysts have issued a strong buy recommendation, reflecting a confident outlook for the company, with a target high price projected at $670.00. This bullish sentiment, coupled with a target mean price of $616.63, suggests substantial growth potential as the company continues to meet evolving healthcare demands. The stock currently trades at $508.00, considerably below its 52-week high of $637.51. Given the low short interest of just 0.0146% of the company’s float, investor sentiment remains stable, adding to the overall positive outlook for McKesson’s stock.
Investment Insights
Investors should note that McKesson’s current stock price, $508.00, lies within the mid-range of its yearly fluctuations, highlighting significant room for growth. The stock’s performance is undercut by its fifty-day moving average of $560.61, suggesting it may be undervalued or facing short-term pressures. With a target low price of $535.00, the forecast indicates potential upside while acknowledging some downside risk. Strong consensus among analysts, with a recommendation mean score of 1.8, further supports McKesson’s attractiveness as an investment option in the competitive healthcare distribution market. Overall, McKesson stands out as a compelling buy, with strong revenue figures and a positive market sentiment backing its growth potential.
| Metric | Value |
|---|---|
| Market Cap | $65.9b |
| Total Debt | $7.4b |
| Total Cash | $2.3b |
| Shares Outstanding | 129.7m |
| Float Shares | 129.4m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.